The drug development company focused on rare diseases has announced top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis. Disappointingly the study did not meet its primary efficacy endpoint (ie shown to have delayed defined adverse events at a P value of 0.05 or less) but was shown to be safe and well tolerated over treatment periods of greater than 4 years. The shares fell 79% on the day to C$0.51.
21 Jun 2016
Where next for BELLUS Health?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Where next for BELLUS Health?
Blue Star Capital Plc (BLU:LON) | 0.0 0 0.0% | Mkt Cap: 1.53m
- Published:
21 Jun 2016 -
Author:
Derren Nathan -
Pages:
6
The drug development company focused on rare diseases has announced top-line Phase 3 results of KIACTA™ for the treatment of AA amyloidosis. Disappointingly the study did not meet its primary efficacy endpoint (ie shown to have delayed defined adverse events at a P value of 0.05 or less) but was shown to be safe and well tolerated over treatment periods of greater than 4 years. The shares fell 79% on the day to C$0.51.